Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
P/E ratio for Rain Therapeutics Inc. (RAIN)
P/E ratio as of 2022: -2.96
According to Rain Therapeutics Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.96. At the end of 2021 the company had a P/E ratio of -4.86.
P/E ratio history for Rain Therapeutics Inc. from 2019 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -2.96 |
| 2021 | -4.86 |
| 2020 | -8.77 |
| 2019 | -15.76 |